Prosecution Insights
Last updated: April 19, 2026
Application No. 18/272,673

SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES

Non-Final OA §103
Filed
Jul 17, 2023
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF Corporation
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 11m
To Grant
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
869 granted / 1225 resolved
+10.9% vs TC avg
Minimal +0% lift
Without
With
+0.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
43 currently pending
Career history
1268
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
14.6%
-25.4% vs TC avg
§102
29.8%
-10.2% vs TC avg
§112
32.5%
-7.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1225 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant's election with traverse of Group II in the reply filed on December 29, 2025 is acknowledged. The traversal is on the ground(s) that lack of unity exists only if a common technical feature lacks novelty or is obvious. Applicants state that unity of invention is evidenced by the International Search Report in that all claims were searched. Applicants further argue that the examiner has not provided proper reasons as to why the groups lack unity of invention. Applicants further argue that the office failed to indicate that the inventions are differently classified and that search and examination would require burden. These arguments have been considered, however, they are not found to be persuasive. Unity of invention is not evidenced by the International Search Report since that report shows that the common technical feature (ie product structure) is known in the art. Applicants arguments for classification and search/examination burden do not apply because these considerations are not relevant to the propriety of restriction in a national stage entry application. The requirement is still deemed proper and is therefore made FINAL. 3. Examination followed guidelines provided by MPEP 803.02. The elected species appeared to be allowable. Therefore, the search and examination was extended. Prior art was found that makes obvious a nonelected species. The Markush claims were rejected and claims to nonelected species were withdrawn from further consideration. The claims were searched to the extent of the elected species and the nonelected species shown below. 4. Claims 14 and 15 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected subject matter. Applicant timely traversed the restriction (election) requirement in the reply filed on December 29, 2025. Status of Claims 5. Claims 1-15 are pending. Claims 1-13 are elected of which claim 1 is independent. Claims 14 and 15 are withdrawn. Priority 6. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement 7. The information disclosure statement (IDS) submitted on July 27, 2023 was in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The IDS was considered. A signed copy of form 1449 is enclosed herewith. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 8. Claim(s) 1-13 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mitra et al. as applied to claims 1-13 above, and further in view of WO 2011161216 and WO 2019201291 (equivalent to US 2021010891). Determining the scope and contents of the prior art Mitra et al. teaches coupling reactions of acetamide and 4-bromofluorobenzene (present claim 9 wherein R is alkyl, and present claims 10 and 11 wherein base is phosphate, and present claim 12 wherein solvent is DMF, and present claim 13 wherein temperature is > 90C) PNG media_image1.png 90 362 media_image1.png Greyscale in the presence of organometallic catalysts comprising various ligands: PNG media_image2.png 808 402 media_image2.png Greyscale . Ascertaining the differences between the prior art and the claims at issue Mitra et al. does not teach the at least one organometallic complex comprising at least one mono or polydentate phosphine ligand. Resolving the level of ordinary skill in the pertinent art and considering objective evidence present in the application indicating obviousness MPEP 2143 B provides basic requirements of prima facie case of obviousness including examples of rationale of the simple substitution of one known element for another to obtain predictable results. To reject a claim based on this rationale the following is considered below and applied to the present claims: A finding that the prior art method differs from claimed method by the substitution of some component with another component Mitra et al. does not teach the at least one organometallic complex comprising at least one mono or polydentate phosphine ligand. The prior art differs from the claims by substitution of a copper catalyst to organometallic complex comprising at least mono or polydentate phosphine ligand. A finding that the substituted components and their functions were known in the art The reference of WO 2011161216 teaches the reaction of 1-chloro-2,6-dibromo-4-fluorobenzene (49.8 mmol), pivalamide (49.8 mmol), Pd(dba)2 (2.490 mmol), 5-bis(diphenylphosphino)-9,9-dimethylxanthene (3.49 mmol) in dioxane at 70 degrees celsius. The Pd(dba)2 and bis(diphenylphosphino)-9,9-dimethylxanthene correspond to the precursor comprising one transition metal which is palladium (present claims 1-5). The reaction thus teaches to molar ratio of transition metal to ligand in the range of 1:1 and molar ratio of compound of formula II as claimed to amide of 1:1 (present claims 7, 8). The reference of WO 2019201291 teaches palladium catalyst [1,1’-bis(diphenylphosphino)ferrocene]palladium dichloride for palladium catalyzed cross coupling (present claim 6). a finding that one of ordinary skill in the art could have substituted one known element for another, and the results of the substitution would have been predictable One of ordinary skill has the knowledge that the coupling reaction of Mitra et al. can be catalyzed by known elements which are other catalysts. The prior art describes organometallic complexes comprising mono or polydentate phosphine ligands as in the claims in a palladium catalyzed C-N coupling. For the reasons provided above, the present claims are found to be prima facie obvious over the prior art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jul 17, 2023
Application Filed
Jan 23, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595251
AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS
2y 5m to grant Granted Apr 07, 2026
Patent 12594266
TRITERPENOID ANTIFUNGALS FOR THE TREATMENT OR PREVENTION OF PNEUMOCYSTIS SPP. PNEUMONIA
2y 5m to grant Granted Apr 07, 2026
Patent 12583854
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12583855
RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583821
SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.4%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 1225 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month